#United States #California #Class Action #Wolf Haldenstein #Unicycive Therapeutics

Wolf Haldenstein Files Class Action on Behalf of Unicycive Shareholders

In a notable development for investors, Wolf Haldenstein Adler Freeman & Herz LLP has initiated a class action lawsuit against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) in the United States District Court for the Northern District of California. This legal move, which relates to the firm’s representation of shareholders who have reportedly suffered financial setbacks, targets individuals and entities who purchased Unicycive securities between March 29, 2024, and June 7, 2025, inclusive.

Key Allegations

The lawsuit alleges that Unicycive, alongside certain executive officers, made deceptive statements regarding:
1. The company's ability to comply with FDA manufacturing standards.
2. The favorable regulatory prospects for its critical drug candidate, oxylanthanum carbonate (OLC), aimed at treating hyperphosphatemia in chronic kidney disease patients undergoing dialysis.

These claims stem from a series of events that significantly impacted the company’s stock price and consequently, investors’ portfolios.

Timeline of Events

• - September 2024: Unicycive submitted its New Drug Application (NDA) for OLC to the FDA, signaling a crucial move that investors expected could lead to a positive outcome.
• - June 10, 2025: Following an announcement that the FDA found manufacturing deficiencies linked to a subcontractor, Unicycive's shares plunged 40.9%, closing at $5.32. This revelation raised alarms about the company’s operational reliability and regulatory compliance.
• - June 30, 2025: In a further setback, the FDA issued a Complete Response Letter rejecting the NDA for OLC due to the same compliance issues. This triggered another disastrous decline in the stock price, dropping 29.9% to $4.77.

The compounding of these events has led to widespread losses for investors, prompting the need for legal action to seek justice and possibly recover financial losses.

Call to Action

Investors who have experienced losses from the Unicycive securities are encouraged to act promptly. The deadline for becoming a lead plaintiff in this matter is October 14, 2025. Wolf Haldenstein urges anyone impacted or who possesses relevant information to contact them directly to discuss potential avenues for participation in the lawsuit.

Why Choose Wolf Haldenstein?

Established in 1888, Wolf Haldenstein has built a reputation as a formidable advocate for investors facing financial damages due to corporate misconduct and misinformation. The firm possesses over 125 years of experience in securities litigation and has a history of effectively representing the rights of investors. This class action lawsuit exemplifies their commitment to championing transparency and accountability in the financial markets.

Contact Information

Phone: (800) 575-0735 or (212) 545-4774
Email: [email protected]
Contact Person: Gregory Stone, Director of Case and Financial Analysis
Firm Website: Wolf Haldenstein

This press release serves to inform current and potential investors about the ongoing legal proceedings and is considered Attorney Advertising in relevant jurisdictions under applicable laws and ethical standards.